Salmon oil trial finds no clear reduction in asthma exacerbations
An exploratory placebo-controlled trial found no statistically significant difference in asthma exacerbations. A numerically longer wait until the first event remained uncertain.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
This trial did not establish that OmeGO reduced asthma exacerbations compared with placebo. The proportion experiencing an exacerbation and the reported event frequency did not differ significantly. Although the first event occurred later numerically in the supplement group, that comparison was also nonsignificant and should not be presented as a demonstrated benefit.
This abstract-based account concerns a small exploratory trial in a specific asthma subgroup. The abstract also describes event frequency using inconsistent weekly and daily wording and does not provide results for its asthma-control assessments.
What researchers found
Participants experiencing at least one asthma exacerbation
OmeGO versus placebo over 20 weeks; the percentage comparison was not statistically significant.
The question behind the trial
Researchers focused on moderate and severe asthma exacerbations, combining them into an event outcome. They also assessed asthma control with a questionnaire and clinical criteria, but the abstract's reported results concentrate on exacerbations.
A numerical difference is uncertain
The authors suggest further study of time to the first event. That is a research question arising from an uncertain result, rather than evidence that the supplement delays attacks. Nonsignificance also does not prove equivalence.
The original publication
The Efficacy of Daily Salmon Oil for Adult Type 2 Asthma: An Exploratory Randomized Double-Blind Trial.
Mølsæter K, Roth K, Myklebust TÅ et al.
Mar Drugs · 2025
- PubMed ID
- 40863645
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.